Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agile Therapeutics Inc AGRX

Alternate Symbol(s):  AGXRW

Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a... see more

Recent & Breaking News (OTCPK:AGRX)

Mid-Morning Market Update: Markets Open Higher; UniFirst Posts Lower Q1 Profit

Benzinga.com  January 4, 2017

15 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 4, 2017

Agile Therapeutics Announces Positive Top-line Phase 3 Results

GlobeNewswire January 3, 2017

Agile Therapeutics to Present at Biotech Showcase 2017

GlobeNewswire December 22, 2016

Agile Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 22, 2016

Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer Program

GlobeNewswire December 1, 2016

Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial

GlobeNewswire November 7, 2016

Agile Therapeutics Reports Second Quarter 2016 Financial Results

GlobeNewswire August 8, 2016

Agile Therapeutics Appoints Seth H. Z. Fischer to its Board of Directors

GlobeNewswire July 28, 2016

Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline

GlobeNewswire July 12, 2016

Agile Therapeutics Strengthens Executive Leadership Team with New Chief Commercial Officer

GlobeNewswire July 6, 2016

Agile Therapeutics to Present at the Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire June 23, 2016

Agile Therapeutics Announces Issuance of Patent for Progestin Patch Designs

GlobeNewswire June 16, 2016

Agile Therapeutics to Present at the William Blair & Company’s 36th Annual Growth Stock Conference

GlobeNewswire June 7, 2016

Agile Therapeutics to Present at the Jefferies 2016 Healthcare Conference

GlobeNewswire June 2, 2016

Agile Therapeutics Reports First Quarter 2016 Financial Results

GlobeNewswire May 9, 2016

Agile Therapeutics to Present at Women's Health 2016: The 24th Annual Congress

GlobeNewswire April 15, 2016

Agile Therapeutics to Present at the 15th Annual Needham Healthcare Conference

GlobeNewswire March 30, 2016

Agile Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire March 9, 2016

Agile Therapeutics to Present at the 28th Annual ROTH Conference

GlobeNewswire March 3, 2016